Pfeiffer, Per

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3,421

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 2,144

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,491

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial

Pfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 232

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

Johansen, J. S., Calatayud, D., Albieri, V., Schultz, N. A., Dehlendorff, C., Werner, J., Jensen, B. V., Pfeiffer, P., Bojesen, S. E., Giese, N., et al. (2016) · International Journal of Cancer

MicroRNA in disease regulationPancreatic and Hepatic Oncology Research

Cited by 47

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 43

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Mezheyeuski, A., Lindh, M. B., Guren, T. K., Dragomir, A., Pfeiffer, P., Kure, E. H., Ikdahl, T., Skovlund, E., Corvigno, S., Strell, C., et al. (2106) · Oncotarget

Cancer Cells and MetastasisAngiogenesis and VEGF in Cancer

Cited by 34

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

Osterlund, E., Ristimäki, A., Kytölä, S., Kuopio, T., Heervä, E., Muhonen, T., Halonen, P., Kallio, R., Soveri, L.-M., Sundström, J., et al. (2022) · Frontiers in Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 23

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: Results of a systematic review and meta-analysis

Yoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S. (2023) · Therapeutic Advances in Medical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 12